Clinical trial NCT00097500 - References

Type 2 Diabetes Mellitus — Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

Citation(s)

•   Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ
  One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated typ

A Phase 3, Randomized, Open Label, Comparator-Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c

Details for clinical trial NCT00097500